Skip to main content
. 2016 Aug 29;101(11):4431–4439. doi: 10.1210/jc.2016-2300

Figure 1.

Figure 1.

Overview of the investigated cohort of pembrolizumab-treated melanoma patients, displaying inclusion criteria and overall thyroid dysfunction.